Agonists of the type 1 cannabinoid receptor (CB1 ... They also activate the β-arrestin signalling pathway, which is associated with side effects and tolerance. Rangari et al.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) signed a binding letter of intent (LOI) to acquire SKNY Pharmaceuticals, Inc. The ...

Chemically modifying a synthetic cannabinoid could enable scientists to capitalize on the body’s natural pain-killing pathway without evoking drug tolerance or psychoactivity. Read the paper ...

Mira Pharmaceuticals is making moves in weight loss and smoking cessation. The biotech is trying to buy Skny Pharmaceuticals ...

CB1R, cannabinoid receptor 1 ... that CB1R activation in the gut epithelium triggers the ERK1/2 signalling pathway, which leads to the downregulation of tight junction proteins and a reduction ...

Heavy alcohol consumption is a leading cause of gastrointestinal diseases, with binge drinking linked to increased intestinal permeability—a condition ...

The drug, known as VIP36, targets the body’s cannabinoid receptor type 1 (CB1 ... previous attempts to target this pathway have been met with two challenges. First, repeated exposure to a drug leads ...

Tucked into a corner of South Yarra where Chapel Street meets Oxford, Astrid Dispensary aims to provide a holistic experience for patients accessing prescribed natural therapies. Established to ...

Heavy alcohol consumption is a leading cause of gastrointestinal diseases, with binge drinking linked to increased intestinal ...